Dorothy Watson

4.3k total citations · 1 hit paper
31 papers, 3.1k citations indexed

About

Dorothy Watson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Dorothy Watson has authored 31 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Dorothy Watson's work include Lung Cancer Research Studies (11 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Dorothy Watson is often cited by papers focused on Lung Cancer Research Studies (11 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Dorothy Watson collaborates with scholars based in United States, Japan and Canada. Dorothy Watson's co-authors include James E. Herndon, Mark R. Green, David J. Sugarbaker, Everett E. Vokes, Gary M. Strauss, David W. Johnstone, Michael A. Maddaus, Elizabeth A. Johnson, Richard L. Schilsky and David H. Harpole and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Dorothy Watson

31 papers receiving 3.0k citations

Hit Papers

Adjuvant Paclitaxel Plus Carboplatin Compared With Observ... 2008 2026 2014 2020 2008 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
    2008 690 citations Gary M. Strauss, James E. Herndon et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dorothy Watson United States 17 2.3k 1.8k 374 302 298 31 3.1k
Panos Fidias United States 25 1.8k 0.8× 1.7k 1.0× 925 2.5× 170 0.6× 269 0.9× 58 3.0k
Paolo Andrea Zucali Italy 37 2.4k 1.0× 1.1k 0.7× 723 1.9× 201 0.7× 435 1.5× 186 4.1k
Tetsu Shinkai Japan 29 1.8k 0.7× 2.0k 1.2× 782 2.1× 338 1.1× 196 0.7× 146 3.2k
Adolfo Favaretto Italy 31 2.2k 0.9× 1.7k 1.0× 780 2.1× 371 1.2× 231 0.8× 136 3.7k
Matteo Giaj Levra France 18 2.3k 1.0× 1.9k 1.1× 599 1.6× 174 0.6× 236 0.8× 70 3.0k
Russell F. DeVore United States 17 2.4k 1.0× 2.8k 1.6× 1.3k 3.4× 374 1.2× 124 0.4× 29 3.8k
Tomonori Hirashima Japan 31 1.9k 0.8× 1.7k 0.9× 543 1.5× 148 0.5× 147 0.5× 146 2.7k
Shinji Atagi Japan 36 3.3k 1.4× 3.2k 1.8× 819 2.2× 491 1.6× 184 0.6× 182 4.5k
Guy A. Van Hazel Australia 18 913 0.4× 1.9k 1.1× 400 1.1× 120 0.4× 158 0.5× 40 2.4k
Miyako Satouchi Japan 37 3.5k 1.5× 2.8k 1.6× 900 2.4× 344 1.1× 543 1.8× 171 4.8k

Countries citing papers authored by Dorothy Watson

Since Specialization
Citations

This map shows the geographic impact of Dorothy Watson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dorothy Watson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dorothy Watson more than expected).

Fields of papers citing papers by Dorothy Watson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dorothy Watson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dorothy Watson. The network helps show where Dorothy Watson may publish in the future.

Co-authorship network of co-authors of Dorothy Watson

This figure shows the co-authorship network connecting the top 25 collaborators of Dorothy Watson. A scholar is included among the top collaborators of Dorothy Watson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dorothy Watson. Dorothy Watson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Innocenti, Federico, Chen Jiang, Alexander B. Sibley, et al.. (2019). An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenetics and Genomics. 29(6). 123–131. 5 indexed citations
2.
Dressler, Lynn G., Allison M. Deal, Kouros Owzar, et al.. (2015). Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). JNCI Journal of the National Cancer Institute. 107(10). djv188–djv188. 8 indexed citations
3.
Hertz, Daniel L., Kouros Owzar, Susan Halabi, et al.. (2013). A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance).. Journal of Clinical Oncology. 31(15_suppl). 11053–11053. 1 indexed citations
4.
Koelwyn, Graeme J., Neil D. Eves, Whitney Hornsby, et al.. (2013). Comparison of performance status with peak oxygen consumption in operable patients with non‐small‐cell lung cancer. Respirology. 19(1). 105–108. 5 indexed citations
5.
Baldwin, R. Michael, Kouros Owzar, Hitoshi Zembutsu, et al.. (2012). A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101. Clinical Cancer Research. 18(18). 5099–5109. 160 indexed citations
6.
Wheeler, Heather E., Eric R. Gamazon, Claudia Wing, et al.. (2012). Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy. Clinical Cancer Research. 19(2). 491–499. 49 indexed citations
7.
Strauss, Gary M., James E. Herndon, Michael A. Maddaus, et al.. (2008). Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. Journal of Clinical Oncology. 26(31). 5043–5051. 690 indexed citations breakdown →
8.
Graziano, Stephen L., James E. Herndon, Mark A. Socinski, et al.. (2008). Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901. Journal of Thoracic Oncology. 3(2). 158–162. 15 indexed citations
9.
Bogart, Jeffrey A., Dorothy Watson, Edward F. McClay, et al.. (2008). Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: Analysis of CALGB phase III trial 9235. Lung Cancer. 62(1). 92–98. 6 indexed citations
10.
Loewen, Gregory, Dorothy Watson, Leslie J. Kohman, et al.. (2007). Preoperative Exercise Vo2 Measurement for Lung Resection Candidates: Results of Cancer and Leukemia Group B Protocol 9238. Journal of Thoracic Oncology. 2(7). 619–625. 97 indexed citations
11.
Strauss, Gary M., James E. Herndon, Michael A. Maddaus, et al.. (2006). Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. Journal of Clinical Oncology. 24(18_suppl). 7007–7007. 137 indexed citations
12.
Edelman, Martin J., Dorothy Watson, X. Wang, et al.. (2006). Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203. Journal of Clinical Oncology. 24(18_suppl). 7025–7025. 9 indexed citations
13.
Clamon, Gerald H., James E. Herndon, Jeffrey A. Kern, et al.. (2005). Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2. Cancer. 103(8). 1670–1675. 93 indexed citations
14.
15.
Bogart, Jeffrey A., et al.. (2005). Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002. Journal of Clinical Oncology. 23(16_suppl). 7170–7170. 4 indexed citations
16.
Bogart, Jeffrey A., James E. Herndon, Alan P. Lyss, et al.. (2004). 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. International Journal of Radiation Oncology*Biology*Physics. 59(2). 460–468. 116 indexed citations
17.
Sherman, Carol A., James E. Herndon, Dorothy Watson, & Mark R. Green. (2004). A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung Cancer. 45(3). 387–392. 12 indexed citations
18.
Otterson, Gregory A., James E. Herndon, Dorothy Watson, Mark R. Green, & Hedy L. Kindler. (2003). Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer. 44(2). 251–259. 81 indexed citations
19.
Halperin, Edward C., Dorothy Watson, & Stephen L. George. (2001). Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma. Cancer. 91(8). 1444–1450. 54 indexed citations
20.
Morrison, Anne, et al.. (1998). Evaluation and eligibility of HLA‐identical sibling donors for stem cell/bone marrow donation. Transfusion Medicine. 8(3). 215–220. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Panos Fidias Breakdown of academic impact, for papers by Paolo Andrea Zucali Breakdown of academic impact, for papers by Tetsu Shinkai Breakdown of academic impact, for papers by Adolfo Favaretto Breakdown of academic impact, for papers by Matteo Giaj Levra Breakdown of academic impact, for papers by Russell F. DeVore Breakdown of academic impact, for papers by Tomonori Hirashima Breakdown of academic impact, for papers by Shinji Atagi Breakdown of academic impact, for papers by Guy A. Van Hazel Breakdown of academic impact, for papers by Miyako Satouchi
Rankless by CCL
2026